Cargando…
Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
[Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586451/ https://www.ncbi.nlm.nih.gov/pubmed/37867693 http://dx.doi.org/10.1021/acsomega.3c05928 |
_version_ | 1785123162780860416 |
---|---|
author | Sıcak, Yusuf Aktar, Bedriye Seda Kurşun Yılmaz, Gizem Tatar Öztürk, Fatma Aydoğmuş Öztürk, Mehmet Tok, Tuğba Taşkın Emre, Emine Elçin Oruç |
author_facet | Sıcak, Yusuf Aktar, Bedriye Seda Kurşun Yılmaz, Gizem Tatar Öztürk, Fatma Aydoğmuş Öztürk, Mehmet Tok, Tuğba Taşkın Emre, Emine Elçin Oruç |
author_sort | Sıcak, Yusuf |
collection | PubMed |
description | [Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure–activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC(50): 17.41 ± 0.22 μM) was the most active against AChE, while compounds 3–26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC(50): 3.22 ± 0.70 mM), 15 (IC(50): 5.19 ± 0.03 mM), 24 (IC(50): 7.21 ± 0.27 mM), 23 (IC(50): 8.05 ± 0.11 mM), 14 (IC(50): 8.10 ± 0.22 mM), 25 (IC(50): 8.40 ± 0.64 mM), 26 (IC(50): 8.76 ± 0.90 mM), and 22 (IC(50): 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC(50): 16.79 ± 0.19 μM), 19 (IC(50): 18.25 ± 0.50 μM), 18 (IC(50): 20.24 ± 0.77 μM), 26 (IC(50): 21.51 ± 0.44 μM), 25 (IC(50): 21.70 ± 0.06 μM), and 24 (IC(50): 22.49 ± 0.11 μM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1–26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes. |
format | Online Article Text |
id | pubmed-10586451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-105864512023-10-20 Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones Sıcak, Yusuf Aktar, Bedriye Seda Kurşun Yılmaz, Gizem Tatar Öztürk, Fatma Aydoğmuş Öztürk, Mehmet Tok, Tuğba Taşkın Emre, Emine Elçin Oruç ACS Omega [Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure–activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC(50): 17.41 ± 0.22 μM) was the most active against AChE, while compounds 3–26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC(50): 3.22 ± 0.70 mM), 15 (IC(50): 5.19 ± 0.03 mM), 24 (IC(50): 7.21 ± 0.27 mM), 23 (IC(50): 8.05 ± 0.11 mM), 14 (IC(50): 8.10 ± 0.22 mM), 25 (IC(50): 8.40 ± 0.64 mM), 26 (IC(50): 8.76 ± 0.90 mM), and 22 (IC(50): 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC(50): 16.79 ± 0.19 μM), 19 (IC(50): 18.25 ± 0.50 μM), 18 (IC(50): 20.24 ± 0.77 μM), 26 (IC(50): 21.51 ± 0.44 μM), 25 (IC(50): 21.70 ± 0.06 μM), and 24 (IC(50): 22.49 ± 0.11 μM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1–26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes. American Chemical Society 2023-10-04 /pmc/articles/PMC10586451/ /pubmed/37867693 http://dx.doi.org/10.1021/acsomega.3c05928 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Sıcak, Yusuf Aktar, Bedriye Seda Kurşun Yılmaz, Gizem Tatar Öztürk, Fatma Aydoğmuş Öztürk, Mehmet Tok, Tuğba Taşkın Emre, Emine Elçin Oruç Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title | Design, Synthesis,
Pharmacological Activities, Structure–Activity
Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title_full | Design, Synthesis,
Pharmacological Activities, Structure–Activity
Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title_fullStr | Design, Synthesis,
Pharmacological Activities, Structure–Activity
Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title_full_unstemmed | Design, Synthesis,
Pharmacological Activities, Structure–Activity
Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title_short | Design, Synthesis,
Pharmacological Activities, Structure–Activity
Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones |
title_sort | design, synthesis,
pharmacological activities, structure–activity
relationship, and in silico studies of novel 5-substituted-2-(morpholinoimino)-thiazolidin-4-ones |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586451/ https://www.ncbi.nlm.nih.gov/pubmed/37867693 http://dx.doi.org/10.1021/acsomega.3c05928 |
work_keys_str_mv | AT sıcakyusuf designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT aktarbedriyesedakursun designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT yılmazgizemtatar designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT ozturkfatmaaydogmus designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT ozturkmehmet designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT toktugbataskın designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones AT emreemineelcinoruc designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones |